Compare Cronos Group Inc (CRON) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs JPMorgan Chase & Co — how do they compare? Cronos Group Inc trades at $2.75 (market cap $1.02B), while JPMorgan Chase & Co trades at $347.07 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 893.6× Cronos Group Inc's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | JPM | |
|---|---|---|
Market Cap | $1.02B | $911.47B |
Sector | Health | Financials |
52-Week High | $3.27 | $342.89 |
52-Week Low | $1.95 | $282.84 |
Enterprise Value | $203.29M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
JPMorgan Chase (JPM) trades at $349.07, up 4.35% over 24 hours, with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growing to $181.85B in 2025 and a net income margin of 31.61%. The stock shows robust fundamentals, including a P/E of 14.69 and ROE of 17.03%, while institutional activity remains positive amid geopolitical and economic uncertainties highlighted in recent news.
The outlook for JPM is positive, driven by earnings momentum and a moderate buy consensus with a $377.75 price target. Key risks include volatile cash flows, cybersecurity threats from AI advancements, and macroeconomic pressures from oil prices and inflation, as noted in CEO Jamie Dimon's warnings. Investors should weigh strong profitability against these headwinds for potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
